121 related articles for article (PubMed ID: 32302424)
1. Treatment of transfusion-dependent congenital dyserythropoietic anemia Type I patients with pegylated interferon alpha-2a.
Abu-Quider A; Asleh M; Shalev H; Fruchtman Y; Ben-Harosh M; Beck G; Kapelushnik J
Eur J Haematol; 2020 Aug; 105(2):216-222. PubMed ID: 32302424
[TBL] [Abstract][Full Text] [Related]
2. Severe congenital dyserythropoietic anaemia type I: prenatal management, transfusion support and alpha-interferon therapy.
Parez N; Dommergues M; Zupan V; Chambost H; Fieschi JB; Delaunay J; Miélot F; Cramer EM; Dommergues JP; Wickramasinghe SN; Tchernia G
Br J Haematol; 2000 Aug; 110(2):420-3. PubMed ID: 10971401
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
4. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Pegylated Interferon Alpha-2b Monotherapy in Hepatitis C Virus-Infected Children with End-Stage Renal Disease on Hemodialysis.
Mogahed EA; Abdelaziz H; Helmy H; Ghita H; Abdel Mawla MA; Hassanin F; Fadel FI; El-Karaksy H
J Interferon Cytokine Res; 2016 Dec; 36(12):681-688. PubMed ID: 27656950
[TBL] [Abstract][Full Text] [Related]
6. Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR).
Niss O; Lorsbach RB; Berger M; Chonat S; McLemore M; Buchbinder D; McCavit T; Shaffer LG; Simpson J; Schwartz JH; Meznarich J; Emberesh M; Seu KG; Zhang W; Kalfa TA;
Blood Cells Mol Dis; 2021 Mar; 87():102534. PubMed ID: 33401150
[TBL] [Abstract][Full Text] [Related]
7. Successful management of transfusion-dependent congenital dyserythropoietic anemia type 1b with interferon alfa-2a.
Rathe M; Møller MB; Greisen PW; Fisker N
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29049846
[TBL] [Abstract][Full Text] [Related]
8. Interferon therapy in congenital dyserythropoietic anemia type I/II.
Marwaha RK; Bansal D; Trehan A; Garewal G
Pediatr Hematol Oncol; 2005 Mar; 22(2):133-8. PubMed ID: 15804998
[TBL] [Abstract][Full Text] [Related]
9. Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma.
Schiller M; Tsianakas A; Sterry W; Dummer R; Hinke A; Nashan D; Stadler R
J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):1841-1847. PubMed ID: 28557110
[TBL] [Abstract][Full Text] [Related]
10. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma.
Hüsken AC; Tsianakas A; Hensen P; Nashan D; Loquai C; Beissert S; Luger TA; Sunderkötter C; Schiller M
J Eur Acad Dermatol Venereol; 2012 Jan; 26(1):71-8. PubMed ID: 22168776
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of pegylated interferon-α2a in patients with lamivudine-resistant HBeAg-positive chronic hepatitis B.
Suh DJ; Lee HC; Byun KS; Cho M; Kweon YO; Tak WY; Chon CY; Koh KC; Lee YS
Antivir Ther; 2013; 18(6):765-73. PubMed ID: 23900457
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China.
Hu Y; Ye YZ; Ye LJ; Wang XH; Yu H
World J Pediatr; 2019 Dec; 15(6):595-600. PubMed ID: 31487005
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
[TBL] [Abstract][Full Text] [Related]
14. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
15. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
Aziz H; Raza A; Waheed Y; Gill U; Gill ML
Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
[TBL] [Abstract][Full Text] [Related]
16. OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.
Carosi G; Bruno R; Cariti G; Nasta P; Gulminetti R; Galli M; Angarano G; Verucchi G; Pontali E; Capetti A; Raise E; Ravasio V; Maida I; Iannacone C; Caputo A; Puoti M
Antivir Ther; 2014; 19(8):735-45. PubMed ID: 24583976
[TBL] [Abstract][Full Text] [Related]
17. Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients.
Gowin K; Thapaliya P; Samuelson J; Harrison C; Radia D; Andreasson B; Mascarenhas J; Rambaldi A; Barbui T; Rea CJ; Camoriano J; Gentry A; Kiladjian JJ; O'Connell C; Mesa R
Haematologica; 2012 Oct; 97(10):1570-3. PubMed ID: 22419578
[TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study.
Liu CH; Liang CC; Lin JW; Chen SI; Tsai HB; Chang CS; Hung PH; Kao JH; Liu CJ; Lai MY; Chen JH; Chen PJ; Kao JH; Chen DS
Gut; 2008 Apr; 57(4):525-30. PubMed ID: 17881538
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
[TBL] [Abstract][Full Text] [Related]
20. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
